MX369774B - Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. - Google Patents
Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.Info
- Publication number
- MX369774B MX369774B MX2015008454A MX2015008454A MX369774B MX 369774 B MX369774 B MX 369774B MX 2015008454 A MX2015008454 A MX 2015008454A MX 2015008454 A MX2015008454 A MX 2015008454A MX 369774 B MX369774 B MX 369774B
- Authority
- MX
- Mexico
- Prior art keywords
- pregn
- treatment
- depressive disorders
- depressive
- disorders
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- CHOUAXDNNAVGHR-NWSAAYAGSA-N (8s,9s,10r,13s,14s,17r)-17-ethynyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C#C)[C@@H]4[C@@H]3CCC2=C1 CHOUAXDNNAVGHR-NWSAAYAGSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747167P | 2012-12-28 | 2012-12-28 | |
| PCT/US2013/076497 WO2014105620A1 (en) | 2012-12-28 | 2013-12-19 | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008454A MX2015008454A (es) | 2016-05-16 |
| MX369774B true MX369774B (es) | 2019-11-21 |
Family
ID=49950051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008454A MX369774B (es) | 2012-12-28 | 2013-12-19 | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10322138B2 (enExample) |
| EP (1) | EP2938346B1 (enExample) |
| JP (1) | JP6283689B2 (enExample) |
| KR (1) | KR102209475B1 (enExample) |
| CN (1) | CN104936600B (enExample) |
| AU (1) | AU2013371025B2 (enExample) |
| CA (1) | CA2894686C (enExample) |
| DK (1) | DK2938346T3 (enExample) |
| ES (1) | ES2625778T3 (enExample) |
| MX (1) | MX369774B (enExample) |
| WO (1) | WO2014105620A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| PL3955933T3 (pl) * | 2019-04-15 | 2024-04-29 | Vistagen Therapeutics, Inc. | Leczenie migreny |
| WO2024254005A1 (en) | 2023-06-04 | 2024-12-12 | Vistagen Therapeutics, Inc. | 1,3,5(10),16-estratetraen-3-yl acetate for use in improving psychomotor or cognitive performance |
| US20250312356A1 (en) * | 2024-04-08 | 2025-10-09 | Vistagen Therapeutics, Inc. | Treatment of dysmenorrhea |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5303703A (en) | 1991-10-03 | 1994-04-19 | Pherin Corporation | Combined neuroepithelial sample delivery electrode device and methods of using same |
| ES2210243T3 (es) * | 1993-06-15 | 2004-07-01 | Pherin Corporation | Esteroides de androstano utiles como iniciadores del cambio de la funcion hipotalamica humana, composiciones farmaceuticas y procedimientos asociados. |
| US6057439A (en) | 1994-08-04 | 2000-05-02 | Pherin Corporation | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
| US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US6066627A (en) | 1994-08-04 | 2000-05-23 | Pherin Corporation | Steroids as neurochemical initiators of change in human blood levels of LH |
| US5994333A (en) * | 1994-08-04 | 1999-11-30 | Pherin Corporation | Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US6331534B1 (en) | 1994-08-04 | 2001-12-18 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to alleviate pain |
| US6117860A (en) | 1994-08-04 | 2000-09-12 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia |
| ATE342721T1 (de) * | 1996-07-23 | 2006-11-15 | Pherin Pharm Inc | Steroide als neurochemische stimulatoren des nasenraumes zur linderung der prämenstrualen symptome |
| US20020123138A1 (en) | 2000-11-30 | 2002-09-05 | Jian Zhang | Human VNO receptor (R1) |
| US20030045514A1 (en) | 2001-05-03 | 2003-03-06 | Louis Monti | 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors |
-
2013
- 2013-12-19 KR KR1020157020176A patent/KR102209475B1/ko active Active
- 2013-12-19 ES ES13819136.6T patent/ES2625778T3/es active Active
- 2013-12-19 CN CN201380062351.9A patent/CN104936600B/zh active Active
- 2013-12-19 EP EP13819136.6A patent/EP2938346B1/en active Active
- 2013-12-19 MX MX2015008454A patent/MX369774B/es active IP Right Grant
- 2013-12-19 CA CA2894686A patent/CA2894686C/en active Active
- 2013-12-19 US US14/134,906 patent/US10322138B2/en active Active
- 2013-12-19 JP JP2015550497A patent/JP6283689B2/ja active Active
- 2013-12-19 WO PCT/US2013/076497 patent/WO2014105620A1/en not_active Ceased
- 2013-12-19 AU AU2013371025A patent/AU2013371025B2/en active Active
- 2013-12-19 DK DK13819136.6T patent/DK2938346T3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2894686C (en) | 2021-05-04 |
| EP2938346B1 (en) | 2017-04-05 |
| KR102209475B1 (ko) | 2021-01-28 |
| JP2016504361A (ja) | 2016-02-12 |
| HK1210421A1 (en) | 2016-04-22 |
| US10322138B2 (en) | 2019-06-18 |
| AU2013371025B2 (en) | 2018-01-18 |
| WO2014105620A1 (en) | 2014-07-03 |
| CA2894686A1 (en) | 2014-07-03 |
| MX2015008454A (es) | 2016-05-16 |
| CN104936600A (zh) | 2015-09-23 |
| ES2625778T3 (es) | 2017-07-20 |
| CN104936600B (zh) | 2018-08-03 |
| JP6283689B2 (ja) | 2018-02-21 |
| DK2938346T3 (en) | 2017-06-12 |
| AU2013371025A1 (en) | 2015-07-09 |
| EP2938346A1 (en) | 2015-11-04 |
| US20140187524A1 (en) | 2014-07-03 |
| KR20150100884A (ko) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269852B (en) | Combined treatments and uses for the treatment of demyelination disorders | |
| IL266159A (en) | Treatment of circadian rhythm disorders | |
| IN2015DN01156A (enExample) | ||
| IN2014DN09434A (enExample) | ||
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| PL2704704T3 (pl) | Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry | |
| KR102297388B9 (ko) | 대사장애를 치료하기 위한 아커만시아의 용도 | |
| IL233715A0 (en) | Treatment of diseases related to the circadian rhythm | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| MY181828A (en) | Bicyclically substituted uracils and the use therapy | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| IN2014CN04014A (enExample) | ||
| IL235058A0 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
| MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
| MX2015008454A (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
| GB201320506D0 (en) | Cyclic amino compounds for the use in the treatment of cardiac disorders | |
| HK40043513B (en) | Interval therapy for the treatment of eye diseases | |
| GB201303721D0 (en) | Compositions for treatment of sleep disorders | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |